Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$570.13 -8.5%	$597.71	$352.77 ▼ $678.21	$34.81B	0.57	318,351 shs	2.01 million shs
BGNE BeiGene		$194.32	$141.31 ▼ $248.16	$18.03B	0.57	299,612 shs	331,608 shs
ONC Beigene	$237.38 +2.2%	$246.37	$141.31 ▼ $287.88	$23.48B	0.35	482,909 shs	456,650 shs
TAK Takeda Pharmaceutical	$14.29 -5.1%	$14.88	$12.58 ▼ $15.43	$45.45B	0.26	1.88 million shs	3.11 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	+1.22%	-3.49%	+13.20%	-5.38%	+56.11%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+15.04%
ONC Beigene	-3.93%	-10.61%	+5.31%	+23,224,999,900.00%	+23,224,999,900.00%
TAK Takeda Pharmaceutical	-0.92%	-1.44%	+4.84%	+10.78%	+13.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.7966 of 5 stars	4.5	2.0	0.0	3.4	1.7	1.9
BGNE BeiGene	1.1958 of 5 stars	3.4	0.0	0.0	0.0	0.8	0.6
ONC Beigene	2.8344 of 5 stars	4.5	0.0	0.0	1.6	1.7	0.6
TAK Takeda Pharmaceutical	2.8091 of 5 stars	0.0	4.0	2.5	2.5	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	2.91	Moderate Buy	$699.28	22.65% Upside
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
ONC Beigene	3.00	Buy	$319.00	34.38% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest BGNE, TAK, ARGX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
4/28/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/24/2025	ONC Beigene	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$334.00 ➝ $334.00
4/21/2025	ONC Beigene	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$311.00 ➝ $317.00
4/17/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$681.00 ➝ $796.00
4/16/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/11/2025	ARGX argenx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00 ➝ $715.00
4/10/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$348.00 ➝ $348.00
4/8/2025	ARGX argenx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00 ➝ $720.00
4/7/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$312.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.19B	15.89	N/A	N/A	$69.22 per share	8.24
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
ONC Beigene	$3.81B	6.16	N/A	N/A	$37.10 per share	6.40
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.35 per share	4.27	$15.39 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$12.59	N/A	52.55	N/A	-2.11%	-1.45%	-1.29%	5/8/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
ONC Beigene	-$881.71M	-$6.14	N/A	334.34	7.73	-25.94%	-25.12%	-14.95%	N/A
TAK Takeda Pharmaceutical	$994.06M	$0.40	35.71	8.66	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)

Latest BGNE, TAK, ARGX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ARGX argenx	$0.98	$13.32	+$12.34	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	-$0.0267	-$0.2305	-$0.2037	-$0.21	$8.02 billion	$7.34 billion
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
2/27/2025	Q4 2024	ARGX argenx	$0.98	$1.58	+$0.60	$11.79	$678.52 million	$761.22 million
2/27/2025	Q4 2024	ONC Beigene	-$0.88	-$1.43	-$0.55	-$1.43	$1.09 billion	$1.13 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.71%	-8.36%	132.50%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
BGNE BeiGene	0.05	1.93	1.72
ONC Beigene	0.05	1.93	1.72
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
BGNE BeiGene	48.55%
ONC Beigene	48.55%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
BGNE BeiGene	7.43%
ONC Beigene	6.62%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	61.06 million	59.29 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
ONC Beigene	9,000	98.91 million	90.59 million	N/A
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

BGNE, TAK, ARGX, and ONC Headlines

Recent News About These Companies

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

May 9 at 12:09 AM | youtube.com

Takeda Pharmaceutical FY Oper Pft Y342.59B Vs Pft Y214.08B

May 8 at 11:28 AM | marketwatch.com

Takeda looks toward 'inflection point' as it eyes new launches to shake off Vyvanse generic impacts

May 8 at 11:28 AM | fiercepharma.com

Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

May 8 at 10:32 AM | benzinga.com

Takeda Pharmaceutical (NYSE:TAK) Hits New 52-Week High - Still a Buy?

May 8 at 4:48 AM | marketbeat.com

Lido Advisors LLC Invests $364,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 8 at 4:29 AM | marketbeat.com

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

May 8 at 2:36 AM | businesswire.com

H-E-B, other retailers accuse pharmaceutical companies of having monopolies

May 7 at 8:25 PM | msn.com

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

May 7 at 1:01 PM | zacks.com

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

May 7 at 10:45 AM | zacks.com

Takeda Pharmaceutical Expected to Post Fourth-Quarter Net Loss -- Earnings Preview

May 7 at 10:23 AM | marketwatch.com

Why Nektar Therapeutics’s (NKTR) Stock Is Down 5.47%

May 6 at 7:20 PM | aaii.com

Novavax, Inc.: Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid in Japan

May 5 at 4:37 PM | finanznachrichten.de

Novavax Announces Improved Financial Terms In Its Agreement With Takeda For Nuvaxovid In Japan

May 5 at 11:36 AM | finanznachrichten.de

Takeda Pharmaceutical Company Limited (NYSE:TAK) Stock Position Lifted by Tower Research Capital LLC TRC

May 5 at 4:04 AM | marketbeat.com

Raymond James Financial Inc. Purchases New Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 5 at 3:26 AM | marketbeat.com

Takeda buys coeliac drug licence from COUR Pharmaceuticals

May 3, 2025 | pharmaphorum.com

Marshall Wace LLP Buys Shares of 76,254 Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 3, 2025 | marketbeat.com

TAK or DSNKY: Which Is the Better Value Stock Right Now?

May 2, 2025 | zacks.com

Aquatic Capital Management LLC Buys 61,927 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 1, 2025 | marketbeat.com

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

April 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

United States Steel's Crash: An Unmissable Buying Opportunity
By Gabriel Osorio-Mazilli | April 11, 2025
View United States Steel's Crash: An Unmissable Buying Opportunity
IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
By Leo Miller | April 12, 2025
View IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Aerospace and Defense Stocks Take Flight After Strong Earnings
By Leo Miller | April 29, 2025
View Aerospace and Defense Stocks Take Flight After Strong Earnings
Walgreens Comeback? Private Equity Circling for a Buyout
By Gabriel Osorio-Mazilli | April 13, 2025
View Walgreens Comeback? Private Equity Circling for a Buyout
CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
By Chris Markoch | April 15, 2025
View CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands

BGNE, TAK, ARGX, and ONC Company Descriptions

argenx NASDAQ:ARGX

$570.13 -52.80 (-8.48%)

Closing price 03:59 PM Eastern

Extended Trading

$569.12 -1.01 (-0.18%)

As of 07:43 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Beigene NASDAQ:ONC

$237.38 +5.13 (+2.21%)

As of 03:52 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Takeda Pharmaceutical NYSE:TAK

$14.28 -0.78 (-5.15%)

Closing price 03:59 PM Eastern

Extended Trading

$14.27 -0.02 (-0.11%)

As of 07:55 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time